Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment - International Journal of Obesity
Source : https://www.nature.com/articles/s41366-023-01254-z
Glucagon-like Peptide-1 receptor agonists (GLP-1 RA) and metabolic and bariatric surgery (MBS) both improve cardiovascular outcomes in patients with severe obesity and type-2 diabetes (T2D). The aim of the present...
Conclusion: In this matched cohort study, MBS was associated with lower risk for MACE compared to treatment with early GLP-1 RA in patients with T2D.
Dual GIP/GLP-1 receptor agonists: new advances for treating type-2 diabetes
Source : https://www.sciencedirect.com/science/article/abs/pii/S0003426623000045?via=ihub
Glucagon-like peptide-1 (GLP-1) receptor agonists currently occupy a privileged place in the management of type-2 diabetes (T2D). Dual glucose-depende...
Relevance: Glucagon-like peptide-1 (GLP-1) receptor agonists currently occupy a privileged place in the management of type-2 diabetes (T2D). Dual glucose-dependent insulinotropic polypeptides (GIP/GLP-1) have been recently developed.
Semaglutide in Obesity: Unmet Needs in Men - Diabetes Therapy
Source : https://link.springer.com/article/10.1007/s13300-022-01360-7
Diabetes Therapy (2023) Cite this article FormalPara Key Summary Points Men were understudied in the STEP Phase 3a clinical program. A number of gender-specific differences in efficacy of semaglutide between...
Relevance: A number of gender-specific differences in efficacy of semaglutide between men and women were identified in subgroup analysis overviews of the STEP program.
First-in-Class Oral Semaglutide Overcoming Barriers of Incretinisation in the Indian Context
patients from other parts of the world. However, subcutaneous treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is limited by their injectable mode of administration. The present review highlights barriers...
Relevance: The present review highlights barriers to incretinisation with GLP-1RAs and the role of first-in-class oral semaglutide in the Indian context and provides guidance to physicians on its initiation and uses.
Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom - Advances in Therapy
Source : https://link.springer.com/article/10.1007/s12325-022-02423-8
Objectives The objective of the current preliminary study was to present the cost-effectiveness analyses submitted to the National Institute for Health and Care Excellence (NICE) (TA10765) that deemed semaglutide 2.4...
Conclusion: Semaglutide 2.4 mg s.c. injection is a cost-effective therapy compared to D&E alone for patients with obesity and weight-related comorbidities in the UK. Sensitivity and scenario analyses confirm the robustness of the analyses.